Cognition Therapeutics, Inc. (CGTX) Analysis

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright has maintained a $3.00 price target for Cognition Therapeutics, Inc. (NASDAQ:CGTX), with an unchanged Buy rating. This potential upside of nearly 640% represents the company’s Phase 2 START Study enrollment success that exceeded 50%. The START Study (NCT05531656), which […]

FDA considering NDA after two 6 months of Phase 3 for Alzheimer Disease? This is huge, so huge you can't even find anything similar to this magnitude in previous neurodegenerative disease treatment. Normally, even super big pharmas like Eli Illy and Eisai/Biogen will have to go through 3-4 years of Phase 3 for the AD and those medicines they developed are full of side effects, expensive, and inconvenient. The recent phase 3 from Biogen that were presented last month during AAIC took 4 years!!...

Over the past few weeks, **Cognition Therapeutics ($CGTX)** has been flying under the radar… but that could change **very soon**. I’ve done my DD, and here’s why this stock could be on the verge of a major breakout — potentially even a **buyout** — especially if FDA news plays out. Oh, and for the record, the last time I posted about $OPEN before its rally, it went up **400%**. 👀 ⸻ 🧠 1. **Alzheimer’s Treatment with Real Momentum – CT1812** CGTX is developing *CT1812*, a drug for Alzheimer's ...

(Disclaimer: I hold a small position of just under 10K) I will note the most important points, please do your own research. Cognition Therapeutics ($CGTX) is shaping up to be one of the most compelling under-the-radar plays in the biotech space right now. With a low float, Fast Track designation, and multiple near-term catalysts, and huge long term potential, the setup is explosive. 🚨 **Upcoming Catalysts (In Order):** 1. **July 29 – AAIC Featured Research Session (8:00–8:45 AM)** CGTX is p...

Not financial advice, just a newer trader trying to find plays with actual science behind them. I have 1200 shares at $0.79 and not going to lie I havent really profited yet, but im gonna hold this one for the long term. They’re in Phase 2 with a drug called CT1812 targeting Alzheimer’s. The latest data showed it may actually protect neurons not just treat symptoms. That’s huge. They already dropped proteomic data showing this effect, and basically nobody’s paying attention yet. Please do your...

$SBET, $SOAR, $CGTX are the play. All low-cap and ready to explode. With rate cuts coming, the pump will be insane. Easy 10x potential. Cognition Therapeutics, a clinical-stage biopharmaceutical company, has recently reported a series of encouraging results and progress for its lead drug, zervimesine. This investigational oral medication is designed to protect nerve cells and has shown potential in mid-stage clinical trials. Key recent highlights include: * Successful End-of-Phase 2 Meeting wi...